All In Biotech

Drug Trial Radar · NCT07622121

Treatment of Chronic Thyroid Eye Disease With MHB018A

A Phase III, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection Treatment in Subjects With Chronic Moderate-to-Severe Thyroid Eye Disease

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Sep 24, 2026

Primary completion

Jul 2028

Study completion Jul 2029

Sponsor

Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.

Conditions

  • Thyroid Eye Disease, TED

Interventions

  • MHB018A injectionDrug

    MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

  • MHB018A injection PlaceboDrug

    6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proptosis response rate at Week 24Time frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hype Clinical Research

    Coral Gables, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.